DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMEDS AI (NASDAQ: MEDS) reported third-quarter 2026 diluted earnings per share of $2.72, reversing a year-earlier loss. Revenue rose 50% sequentially to $2,668,980 but fell from $3,012,904 a year earlier. Net income was $10,535,560 versus a $34,318,204 loss. A $19,064,881 debt-extinguishment gain supported earnings; operations still lost $3,373,956, versus $31,548,329 a year earlier.
DataMEDS acquired cancer diagnostics laboratory Helomics in September and obtained an exclusive REBOOT GLP-1 patient-management license in October. Full Nasdaq compliance was restored October 19. In November, it signed a non-binding memorandum with a Florida HMO covering planned app deployment to 25,000+ members; definitive agreements are expected in fourth-quarter 2026. DataMEDS expects continued fourth-quarter revenue growth. At September 30, current liabilities were $37,913,456 against $5,220,035 in current assets.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointThird-quarter net income of $10,535,560 reversed a $34,318,204 year-earlier loss.
- Moderate pointThird-quarter revenue of $2,668,980 rose 50% sequentially but declined from $3,012,904 a year earlier.
- Moderate pointThird-quarter gross profit increased to $431,880 from $231,012 a year earlier.
- Moderate pointThird-quarter operating loss narrowed to $3,373,956 from $31,548,329 a year earlier.
- Moderate pointTotal liabilities declined to $38,562,173 from $42,907,250 at December 31, 2025.
- Moderate pointTotal stockholders’ equity reached $171,695 versus a $12,447,801 deficit at December 31, 2025.
- Moderate pointHelomics acquisition completed in September 2026, adding a CLIA-certified cancer diagnostics laboratory.
- Moderate pointExclusive REBOOT GLP-1 license obtained in October 2026 includes the patient-management platform and related intellectual property.
- Moderate pointFull Nasdaq compliance, including the net equity requirement, was restored October 19, 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Florida HMO memorandum provides for planned Health Lives Here app deployment to 25,000+ members.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter revenue growth is expected by DataMEDS based on added medical-food and diagnostic-testing revenue streams.
13 minor points
- Minor pointDiluted EPS of $2.72 and basic EPS of $3.29 reversed year-earlier losses of $23.07 each.
- Minor pointThird-quarter operating expenses fell to $3,805,836 from $31,779,341 a year earlier.
- Minor pointDebt extinguishment generated a third-quarter gain of $19,064,881 versus a $1,353,663 year-earlier loss.
- Minor pointThird-quarter other income increased to $703,014 from $9,095 a year earlier.
- Minor pointNine-month net loss narrowed to $15,570,262 from $73,421,571 a year earlier.
- Minor pointNine-month loss per share narrowed to $5.89 from $58.78, basic and diluted.
- Minor pointNine-month operating loss narrowed to $16,734,548 from $68,397,073 a year earlier.
- Minor pointNine-month operating expenses declined to $17,518,853 from $69,826,478 a year earlier.
- Minor pointNine-month debt-extinguishment gain was $10,183,187 versus a $1,353,663 year-earlier loss.
- Minor pointNine-month other income increased to $1,312,911 from $33,002 a year earlier.
- Minor pointCash and cash equivalents increased to $476,598 at September 30, 2026, from $42,571 at December 31, 2025.
- Minor pointChemoFx Assay coverage under Humana’s South Carolina Medicaid policy became effective July 22, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional Helomics testing services are being added to support patient groups beyond cancer, especially GLP-1 patients.
Negative
- Major pointCurrent liabilities of $37,913,456 exceeded current assets of $5,220,035 at September 30, 2026.
- Major pointVendor-obligation extinguishment losses totaled $3,605,978 for the quarter and $3,666,098 for nine months, versus none a year earlier. 93% of market cap
- Major pointConvertible notes payable, net of debt discount reached $15,275,679 at September 30, 2026, versus none at year-end.
- Major pointCommon shares outstanding increased to 2,836,484 from 2,026,150 at December 31, 2025, diluting existing holders.
- Moderate pointNine-month revenue fell to $6,008,403 from $21,667,212 a year earlier.
- Moderate pointNine-month gross profit declined to $784,305 from $1,429,405 a year earlier.
- Moderate pointNine-month interest expense, net increased to $5,886,320 from $3,703,837 a year earlier.
- Moderate pointNine-month contract termination fee loss was $766,394, versus none a year earlier. 20% of market cap
- Moderate pointPurchase consideration liability was $1,885,700 at September 30, 2026, versus none at December 31, 2025.
- Moderate pointFlorida HMO memorandum remains non-binding; definitive agreements are expected in fourth-quarter 2026.
2 minor points
- Minor pointThird-quarter interest expense, net increased to $2,252,401 from $1,425,307 a year earlier.
- Minor pointNine-month settlement fees were $13,000, versus none a year earlier.
News Explained
The compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
DataMEDS says it launched the Health Lives Here app and partnered with NFL Alumni Health; the app gives Corexa Pharmacy a customer-acquisition route to dispense FDA-approved GLP-1 medications and Forzet medical food.
Corexa Pharmacy also launched compounded peptides under FDA’s Enforcement Discretion Policy, which the company describes as an incremental revenue opportunity.
Key Figures
- Sequential revenue growth
- 50%
- Third quarter 2026 vs. second quarter 2026
- Net revenues
- $2,668,980
- Q3 2026; vs. $3,012,904 in Q3 2025
- Net income before taxes
- $10,535,560
- Q3 2026; vs. a net loss before taxes of $34,318,204 in Q3 2025
- Diluted net profit per share
- $2.72
- Quarter ended September 30, 2026
- HMO members
- 25,000+ members
- Potential deployment under a non-binding MOU
Key Terms
smart contracts technical
clia-certified regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / November 13, 2026 / DataMEDS AI, Inc. ("DataMEDS AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
"Corexa Pharmacy drove a
Business Update
- Health Lives Here and NFL Alumni Health. The Company launched the Health Lives Here mobile application, partnered with the NFL Alumni Health marketing platform. The app gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1 medications and Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies.
- REBOOT GLP-1 license. In October 2026, DataMEDS obtained an exclusive license to the REBOOT GLP-1 patient management platform and related intellectual property. The Company believes these patented, AI-assisted patient management services create a moat that supports scaling customer acquisition and increasing long-term customer value.
- Compounded peptides. In November 2026, Corexa Pharmacy launched compounded peptides under FDA's Enforcement Discretion Policy published in the Federal Register on October 30, 2026, adding an incremental revenue opportunity. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
- First HMO relationship. In November 2026, the Company signed a non-binding memorandum of understanding with a Florida-based HMO to deploy the Health Lives Here app to its 25,000+ members, providing a platform to optimize user engagement for an institutional customer base. Definitive agreements are expected in the fourth quarter of 2026.
- Helomics. In September 2026, DataMEDS acquired Helomics Corporation, a Pittsburgh-based CLIA-certified cancer diagnostics laboratory. Humana's South Carolina Medicaid coverage policy for the proprietary ChemoFx® Assay, effective July 22, 2026, adds an incremental proprietary revenue stream and opens the cancer pharmaceuticals market for Corexa Pharmacy. Additionally, Helomics' biobank of 70,000+ primary tumor biopsies creates drug discovery opportunities. The Company is adding additional testing services to Helomics' test menu to allow it to support patient groups beyond cancer, especially GLP-1 patients.
- Nasdaq compliance. On October 19, 2026, the Company regained full compliance with Nasdaq listing standards, including the net equity requirement.
Profit from Operations:
The Company recorded a net operating profit of
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.
For more information on DataMeds Ai, Inc., refer to www.datamedsai.com.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ: MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the Company's future revenue growth and financial results, including whether Corexa Pharmacy dispensing revenue continues to grow; customer acquisition through the Health Lives Here app and the NFL Alumni Health marketing platform, and related-party arrangements with Tollo Health, LLC; the scope, enforceability and competitive value of the REBOOT license and related intellectual property; Corexa Pharmacy's ability to compound and dispense peptides in compliance with FDA's Enforcement Discretion Policy and state pharmacy laws, and the possibility that the policy is changed or withdrawn; the non-binding nature of the HMO memorandum of understanding and the possibility that definitive agreements are not executed on the expected timeline or at all; the integration of Helomics and its ability to grow ChemoFx testing volumes and reimbursement; demand for GLP-1 medications and Forzet™ and the regulatory status of medical foods; compliance with healthcare laws, including federal and state anti-kickback, beneficiary inducement and privacy laws; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
PART I-FINANCIAL INFORMATION
Item 1. Financial Statements.
DATAMEDS AI, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 476,598 | $ | 42,571 | ||||
Accounts receivable, net | 1,966,605 | 1,137,219 | ||||||
Inventories, net | 1,440,296 | 1,639,426 | ||||||
Due from related parties | 1,162,125 | - | ||||||
Prepaid and other current assets | 174,411 | - | ||||||
Total current assets | 5,220,035 | 2,819,216 | ||||||
Property, plant and equipment, net | 323,305 | 229,376 | ||||||
Capitalized software | 2,345,268 | 1,850,358 | ||||||
Operating lease, right-of-use-assets | 1,590,240 | 966,893 | ||||||
Goodwill | 15,787,176 | 14,193,923 | ||||||
Other intangible assets, net | 13,249,358 | 10,314,675 | ||||||
Investment in SAFE | 35,000 | - | ||||||
Deposits and other assets | 183,486 | 85,008 | ||||||
Total assets | $ | 38,733,868 | $ | 30,459,449 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 13,061,543 | $ | 11,665,135 | ||||
Accounts payable, related party | 25,500 | 25,500 | ||||||
Accounts payable | 25,500 | 25,500 | ||||||
Accrued expenses and other liabilities | 3,647,245 | 6,407,722 | ||||||
Purchase consideration liability | 1,885,700 | - | ||||||
Due to related parties | - | 225,000 | ||||||
Convertible notes payable, net of debt discount | 15,275,679 | - | ||||||
Current portion of debt obligations, net of debt discount | 2,788,058 | 10,887,520 | ||||||
Operating lease liabilities- current portion | 1,229,731 | 569,251 | ||||||
Total current liabilities | 37,913,456 | 29,780,128 | ||||||
Note payable, net of discount | 100,000 | 12,600,000 | ||||||
Operating lease liabilities | 548,717 | 527,122 | ||||||
Total liabilities | $ | 38,562,173 | $ | 42,907,250 | ||||
Commitments and contingencies (Note 15) | - | - | ||||||
Stockholders' equity (deficit): | ||||||||
Common stock, | 473 | 203 | ||||||
Additional paid-in capital | 124,851,605 | 98,583,686 | ||||||
Accumulated deficit | (126,547,748 | ) | (111,031,690 | ) | ||||
Total DataMeds AI, Inc. stockholders' equity (deficit) | (1,695,670 | ) | (12,447,801 | ) | ||||
Non-controlling interest | 1,867,365 | - | ||||||
Total stockholders' equity (deficit) | 171,695 | (12,447,801 | ) | |||||
Total liabilities and stockholders' equity (deficit) | $ | 38,733,868 | $ | 30,459,449 | ||||
DATAMEDS AI, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Net revenues | $ | 2,668,980 | $ | 3,012,904 | $ | 6,008,403 | $ | 21,667,212 | ||||||||
Cost of net revenues | 2,237,100 | 2,781,892 | 5,224,098 | 20,237,807 | ||||||||||||
Gross profit (loss) | 431,880 | 231,012 | 784,305 | 1,429,405 | ||||||||||||
Operating expenses: | ||||||||||||||||
General and administrative | 3,343,627 | 30,172,800 | 15,269,233 | 66,205,669 | ||||||||||||
Sales and marketing | 105,788 | 803,747 | 1,179,778 | 1,212,347 | ||||||||||||
Depreciation and amortization | 356,421 | 802,794 | 1,069,842 | 2,408,462 | ||||||||||||
Total operating expenses | 3,805,836 | 31,779,341 | 17,518,853 | 69,826,478 | ||||||||||||
Loss from operations | (3,373,956 | ) | (31,548,329 | ) | (16,734,548 | ) | (68,397,073 | ) | ||||||||
Other income (expense): | - | |||||||||||||||
Interest expense, net | (2,252,401 | ) | (1,425,307 | ) | (5,886,320 | ) | (3,703,837 | ) | ||||||||
Loss on extinguishment of vendor obligation | (3,605,978 | ) | - | (3,666,098 | ) | - | ||||||||||
Gain (loss) on extinguishment of debt | 19,064,881 | (1,353,663 | ) | 10,183,187 | (1,353,663 | ) | ||||||||||
Loss on contract termination fee | - | - | (766,394 | ) | - | |||||||||||
Settlement fees | - | - | (13,000 | ) | - | |||||||||||
Other income | 703,014 | 9,095 | 1,312,911 | 33,002 | ||||||||||||
Total other income (expense), net | 13,909,516 | (2,769,875 | ) | 1,164,286 | (5,024,498 | ) | ||||||||||
Net income (loss) before income taxes | 10,535,560 | (34,318,204 | ) | (15,570,262 | ) | (73,421,571 | ) | |||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
Net income (loss) | $ | 10,535,560 | $ | (34,318,204 | ) | $ | (15,570,262 | ) | $ | (73,421,571 | ) | |||||
Net loss attributable to non-controlling interest | (54,204 | ) | - | (54,204 | ) | - | ||||||||||
Net income (loss) attributable to DataMeds AI | $ | 10,589,764 | $ | (34,318,204 | ) | $ | (15,516,058 | ) | $ | (73,421,571 | ) | |||||
Weighted average common shares outstanding - basic and diluted | ||||||||||||||||
Basic | 3,214,663 | 1,487,588 | 2,636,382 | 1,249,164 | ||||||||||||
Diluted | 3,961,210 | 1,487,588 | 2,636,382 | 1,249,164 | ||||||||||||
Net loss per common share - basic and diluted | ||||||||||||||||
Basic | $ | 3.29 | $ | (23.07 | ) | $ | (5.89 | ) | $ | (58.78 | ) | |||||
Diluted | $ | 2.72 | $ | (23.07 | ) | $ | (5.89 | ) | $ | (58.78 | ) | |||||
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were DataMEDS AI’s third-quarter 2026 earnings and revenue?
DataMEDS reported $2,668,980 in revenue and $2.72 diluted earnings per share for the quarter ended September 30, 2026. Revenue increased 50% sequentially but was below $3,012,904 a year earlier. Net income was $10,535,560, supported by a $19,064,881 debt-extinguishment gain, while operations recorded a $3,373,956 loss.
Is DataMEDS AI’s Florida HMO agreement binding?
The November 2026 Florida HMO memorandum is non-binding, with definitive agreements expected in fourth-quarter 2026. It concerns deployment of the Health Lives Here app to the HMO’s 25,000+ members.